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Our study aims to describe trends in new case detection rate (NCDR) of lep-
rosy in Brazil from 2006 to 2017 overall and in subgroups, and to analyze the 
evolution of clinical and treatment characteristics of patients, with emphasis 
on cases diagnosed with grade 2 physical disabilities. We conducted a descrip-
tive study to analyze new cases of leprosy registered in the Brazilian Informa-
tion System for Notificable Diseases (SINAN), from 2006-2017. We calcu-
lated the leprosy NCDR per 100,000 inhabitants (overall and for individuals 
aged < 15 and ≥ 15 years) by sex, age, race/ethnicity, urban/rural areas, and 
Brazilian regions, and estimated the trends using the Mann-Kendall non-
parametric test. We analyzed the distributions of cases according to relevant 
clinical characteristics over time. In Brazil, there was a sharp decrease in the 
overall NCDR from 23.4/100,000 in 2006 to 10.3/100,000 in 2017; among 
children < 15 years, from 6.94 to 3.20/100,000. The decline was consistent in 
all Brazilian regions and race/ethnicity categories. By 2017, 70.2% of the cases 
were multibacillary, 30.5% had grade 1 (G1D) or 2 (G2D) physical disabilities 
at diagnosis and 42.8% were not evaluated at treatment completion/discharge; 
cases with G2D at diagnosis were mostly detected in urban areas (80%) and 
5% of cases died during the treatment (leprosy or other causes). Although the 
frequency of leprosy NCDR decreased in Brazil from 2006 to 2017 across all 
evaluated population groups, the large number of cases with multibacillary 
leprosy, physical disabilities or without adequate evaluation, and among chil-
dren suggest the need to reinforce timely diagnosis and treatment to control 
leprosy in Brazil.
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Introduction
Leprosy is a chronic infectious disease caused by Mycobacterium leprae. In the absence of early diag-
nosis and adequate treatment, infections may lead to serious neurological impairment and poten-
tially irreversible complications, including sensory loss, amyotrophy, deformities, and wounds on the 
hands and feet. Leprosy-associated disabilities can lead to social stigma, discrimination and deteriora-
tion of mental health, which may contribute to job loss and the perpetuation of the cycle of poverty 1.
In 2017, approximately 13% of the more than 200,000 cases of leprosy occurring globally were 
recorded in Brazil 2. Although the Brazilian leprosy control program data shows marked reduction in 
the frequency of leprosy in the general population in recent years, the distribution of leprosy is highly 
heterogeneous across Brazil 3. Clusters of leprosy cases, which are greatly significant for the public 
health, have been detected in the North, Central West, and Northeast regions 3,4. Several capitals in the 
North and Northeast regions of the country have reported no reductions in leprosy cases in children 
aged under 15 years, suggesting there may be active transmission in these populations 5.
Although social protection policies implemented in Brazil in the past decade have been associ-
ated with reduced incidence of leprosy in high-burden municipalities, recent austerity policies and 
increasing poverty rates in the country may have pushed leprosy incidence to higher levels and repre-
sented a set-back in Brazilian leprosy elimination targets 6,7. To understand the effect of these shifting 
pressures, this study aimed to describe the leprosy trends over time in the overall population and in 
subgroups and to analyze the distribution of clinical and treatment characteristics of patients diag-
nosed with leprosy in Brazil, with an emphasis on cases diagnosed with grade 2 physical disabilities 
(G2D). An improved understanding of the epidemiological profile of leprosy in Brazil and the cases 
diagnosed with advanced disease will help to quantify the burden of disease. In addition, this work 
will inform national strategies for prioritizing leprosy control interventions, including health promo-
tion/education, contact surveillance/case finding, and disability treatment/rehabilitation.
Methods
Design, data source and study population
This is a descriptive study that analyzed new cases of leprosy reported in Brazil between 2006 and 
2017. The analysis is based on: (i) de-identified leprosy records obtained from the Brazilian Informa-
tion System for Notificable Diseases (SINAN-leprosy) (2006-2017); and (ii) demographic data from 
the population census of the Brazilian Institute of Geography and Statistics (IBGE) (2000 and 2010). 
The SINAN-leprosy data were obtained in March 2019 with the Citizens’ Information Service Elec-
tronic System (e-SIC; https://esic.cgu.gov.br/falabr.html). This study dataset included records from 
all new cases of leprosy detected between January 1, 2006, and December 31, 2017.
Variables and data analysis
The data extracted from SINAN-leprosy included demographic and socioeconomic variables, i.e., 
age, sex, schooling, race/ethnicity, region of residence in Brazil and residential area (rural and urban); 
clinical variables, i.e., clinical form (indeterminate, tuberculoid, borderline and lepromatous); opera-
tional classification (paucibacillary or multibacillary), grade of physical disability at time of diagnosis 
and at the end of the treatment (grade 0 – G0D, grade 1 – G1D, and grade 2 – G2D); presence of lep-
rosy reaction during treatment (reaction 1, 2, or 1+2); and treatment outcome (cure, transfer to other 
health units, municipalities or state, dropout, or death).
The population composition of Brazil was obtained from 2000 to 2017 overall and by state. From 
2000 to 2017, yearly population distributions were available for age and sex, but were not available for 
the variables of race/ethnicity and residential area (rural or urban). Hence, for comparability between 
the four variables, i.e., age, sex, race/ethnicity and residential area, we used linear interpolation and 
extrapolation based on the 2000 and 2010 census data to calculate the population distributions for 
the years of 2006-2009 and 2011-2017.
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We conducted a descriptive analysis, including the absolute numbers and frequencies and/or 
means and standard deviations (SD) to investigate the distribution of sociodemographic characteristic 
of individuals who were newly diagnosed with leprosy in the study period (2006-2017). We estimated 
the annual new case detection rate (NCDR) of leprosy per 100,000 individuals across the full popu-
lation of Brazil and by geographic (i.e., region of Brazil and residential area) and sociodemographic 
variables (i.e., sex, age, and race/ethnicity) from 2006 to 2017. We also calculated the male:female 
ratio of the number of new leprosy cases detected and estimated leprosy reductions from 2006 to 
2017 NCDR as 1 - NCDR2017/NCDR2006 in order to verify changes over time. The leprosy NCDR 
trends by sociodemographic characteristics were evaluated using the Mann-Kendall non-parametric 
test, which tests if the time series has a monotonic tendency over time. Kendall’s correlation coeffi-
cients were estimated to evaluate if the correlations between the series of detection rates versus time 
were positive or negative. Finally, we conducted a secondary descriptive analysis to investigate the 
distribution of sociodemographic and clinical characteristics of new leprosy cases diagnosed with 
G2D in 2006 and 2017.
All analyses were carried out using R Studio 5.4.1 (http://www.r-project.org) and Stata version 15 
(https://www.stata.com).
Ethical aspects
Three Research Ethics Committees approved this study: (i) the University of Brasília (1.822.125), (ii) 
the Gonçalo Muniz Institute/Oswaldo Cruz Foundation (1.612.302), and (iii) the London School of 
Hygiene & Tropical Medicine (10580-1).
Results
Leprosy NCDR trends
Between 2006 and 2017, a total of 396,989 new cases of leprosy were recorded in Brazil. Overall, the 
NCDR decreased from 23.4/100,000 in 2006 to 10.2/100,000 in 2017 (56.4% reduction) (Table 1). 
Although reductions in NCDR occurred in all five country regions, the magnitude of these declines 
varied. Specifically, the highest reductions between 2006 and 2017 took place in the South (70.9% 
reduction), Southeast (67.8% reduction) and North regions (63.5% reduction) (versus 50% reduc-
tions in North and 49.9% in the Central West) (Figure 1a). As of 2017, the Central West (NCDR2017: 
25.7/100,000) and North regions (NCDR2017: 22.8/100,000) had the highest leprosy detection coef-
ficients. Downward trends in the overall leprosy NCDR were observed in both the urban and rural 
areas (Figure 1b), among both men and women (Figure 1c) and across all ages (Figure 1d) and racial/
ethnic groups (Tables 1 and 2). Among children aged under 15 years, 25,688 new cases of leprosy 
were identified during the study period, equivalent to 6.5% of all the cases in the country. The NCDR 
among children was approximately halved from 6.9/100,000 in 2006 to 3.2/100,000 in 2017.
Despite the widespread decreases in leprosy NCDR from 2006 to 2017, it remained dispropor-
tionately higher in some groups – the NCDR among men was higher than that among women across 
all years evaluated, and the male:female ratio of 1:2 remained consistent over time (Table 1). Similarly, 
the highest NCDR was consistently observed among individuals aged 60 or older. Overall, the age at 
new case detection became higher over time, with the mean age increasing from 41.9 years (SD = 20.2) 
in 2006 to 46.3 years (SD = 19.8) in 2017. The highest NCDRs were also recorded in 2017 for indi-
viduals self-identified as Black (15.3/100,000), Indigenous (14.2/100,000) and Brown (13.1/100,000) 
(Table 1). Whereas one of the highest NCDRs were recorded among the indigenous population, the 
number of cases was much smaller than in other racial/ethnic groups.
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Table 1
Frequency and new case detection rate (NCDR) of leprosy per 100,000 population by sociodemographic characteristics and residential area in Brazil 
from 2006 to 2017 (N = 396,989). 
Variables 2006-2017 2006 2017 Reduction * (%)
N % Mean NCDR n NCDR n NCDR
Total 396,989 16.9 43,744 23.4 21,244 10.2 56.3
Region
North 79,568 40.6 40.6 9,384 62.5 4,095 22.8 63.5
Northeast 165,630 25.4 25.4 16,977 32.9 9,403 16.4 50.0
Southeast 68,317 6.9 6.9 8,645 10.9 3,043 3.5 67.8
South 15,677 4.6 4.6 1,950 7.1 617 21 70.9
Central West 67,723 38.9 38.9 6,845 51.6 4,081 25.7 49.9
Sex
Female 177,646 44.8 15.5 20,151 21.7 9,630 9.2 57.8
Male 219,322 55.3 23,621 26.4 11,614 11.6 56.1
Male:Female ratio 13.8 1.17 1.21
Age group (years) 17.7
< 15 28,729 7.2 3,311 6.9 1,371 3.2 53.9
15- 59 285,176 71.8 32,635 28.0 14,510 10.5 62.4
60+ 83,084 20.9 4.9 7,828 43.1 5,363 21.6 49.9
Race/Ethnicity 17.2
White 113,139 28.5 29.5 13,933 15.3 5,188 5.8 62.5
Brown/Mixed race 50,938 12.8 21,561 28.4 12,481 13.1 65.1
Black 209,928 52.9 9.6 5,622 43.8 2,604 15.3 53.8
Asian 4,394 1.1 26.1 624 39.8 210 6.9 82.7
Indigenous 1,616 0.4 18.8 127 16.2 125 14.2 12.3
Missing 14.9 1,907 636
Residential area 307,459 77.5 15.0 48.9
Urban 60,870 15.3 28,712 18.9 17,107 9.7 31.5
Rural 177,646 44.8 14.3 5,553 18.1 3,514 12.4 57.8
Missing 9,509 623 56.1
Source: Brazilian Health Informatics Department (DATASUS) – http://www2.datasus.gov.br/DATASUS/index.php?area=0901 (accessed on 03/May/2019) 
and http://tabnet.datasus.gov.br/cgi/deftohtm.exe?popsvs/cnv/popbr.def (acccessed on 24/May/2019). 
* Reduction of leprosy NCDR estimated by 1 - NCDR2017/NCDR2006.
Evolution of leprosy diagnosis over time
Between 2006 and 2017, the proportion of leprosy cases detected with severe manifestations of the 
disease increased over time (Table 3). Specifically, the percentage of borderline leprosy cases increased 
from 31.6% to 47%, which corresponded to reductions in the tuberculoid and indeterminate forms. 
In addition, multibacillary cases increased from 52.9% to 70.2% (Table 3). The proportion of cases 
without reaction episodes during treatment doubled (from 32.2% to 66.4%), and in 2017, the majority 
of cases were evaluated for reaction (40.4% vs. 78.6%). Also, in 2017, there was a larger proportion of 
cases that transferred to treatment in other health units (5.9% in 2006 vs. 11.4% in 2017).
Although there was an overall reduction in the number of new cases, the percentage of cases with 
G1D or G2D disabilities increased from 22.6% in 2006 to 30.5% in 2017 (Figure 2a, Table 3), resulting 
in a NCDR of G2D of 6.92/1,000,000 cases in 2017 (data not shown). Similar trends were observed 
for children (Figure 2b), with NCDR of G2D of 0.91/1,000,000 children in 2017.
Over time, G1D and G2D contributed to a substantial number of new cases at diagnosis and at the 
end of treatment (Figure 3, Table 3). In 2017, among the 5,032 cases evaluated with G1D at diagnosis, 
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Figure 1
New case detection rate (NCDR) of leprosy per 100,000 population by region of residence, urban and rural regions, sex, and age groups in Brazil from 
2006 to 2017.
Note: for 1b, the rate differences in rates from national Brazilian data represents missing data.
1,459 (29%) remained with G1D; 141 cases (2.8%) progressed to more severe disability grades (G2D) 
and for 1,985 (39.4%) there was no information on patients’ disability grades at the end of treatment 
(Table 4, Figure 3). Among the cases diagnosed with G2D in 2017, 22.4% of cases improved to G0D 
or G1D, but 35% remained with G2D and for 42.7% the information on patients’ disability grades at 
the end of treatment was not documented by a physician or health professional (Table 4, Figure 3). 
Overall, the disability grade at the end of treatment was not evaluated for 46.4% of cases in 2006 and 
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Table 2
Time trends in the socioeconomic and demographic characteristics of new leprosy cases in Brazil from 2006 to 2017 
evaluated using the Mann-Kendall test for monotonic trends and the Kendall rank correlation coefficient. 






< 15 -58.00 * -0.88
15-59 -52.00 * -0.79
60+ -66.00 * -0.99
Race/Ethnicity
White -64.00 * -0.97
Black -64.00 * -0.97
Asian -66.00 * -0.99
Brown/Mixed race -64.00 * -0.97
Indigenous -30.00 * -0.45
Region
North -64.00 * -0.97
Northeast -64.00 * -0.97
Southeast -66.00 * -0.99
South -66.00 * -0.99
Central West -54.00 * -0.82
Residential area
Urban -56.00 * -0.85
Rural -40.00 * -0.61
* Evidence of trend effect.
42.8% of cases in 2017 (Figure 3). A larger proportion transferred out to other health units (5.9% in 
2006 vs. 11.4% in 2017).
Among the subgroup of new cases with G2D, between 2006 and 2017 we observed increases in 
the percentages of individuals who were aged over 60 (32.4% to 40.1%), identified as Brown (44% to 
55%), resident in urban areas (60% to 80%), and that were classified as multibacillary cases (88% to 
95%). Although the number of cases evaluated for reaction episodes during treatment decreased from 
52.6% to 20.6% in 2017, among those evaluated in 2017, 29% (331/1,140) reported having some type 
of reaction episode. The proportion of G2D cases that were transferred out to continue treatment in 
other health units was 15% in 2017 and almost 5% have died during treatment as result of leprosy or 
from other causes (Table 5).
Discussion
This study described the epidemiological context for leprosy in Brazil and its regions in a historic 
series spanning twelve years. Between 2006 and 2017, despite overall reductions in the leprosy new 
case detection rates (reductions of over 50%), Brazil continued to experience a high incidence of lep-
rosy in the Central West, North, and Northeast regions, among men, individuals aged over 60 years, 
and individuals who identified as non-White (Black, Brown and Indigenous). There was an increased 
proportion of individuals newly diagnosed with multibacillary leprosy or diagnosed with leprosy-
associated G1D or G2D, including a substantial number of children that continue to be detected 
with G2D.
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Table 3
Total number and percentage of new leprosy cases by clinical characteristics in Brazil from 2006 to 2017. 
Clinical variables 2006 2017
n % n %
Total 43,774 100.0 21,244 100.0
Clinical form
Undeterminate 8,986 20.5 3,141 14.8
Tuberculoid 10,449 23.9 3,301 15.5
Borderline 13,840 31.6 9,983 47.0
Lepromatous 6,809 15.6 3,008 14.2
Not reported 3,690 8.4 1,811 8.6
Operational classification
Paucibacillary 20,526 46.9 6,328 29.8
Multibacillary 23,145 52.9 14,916 70.2
Not reported 103 0.2 0 0.0
Disability grade at diagnosis
Grade 0 29,811 68.1 12,375 58.3
Grade 1 7,495 17.1 5,032 23.7
Grade 2 2,416 5.5 1,436 6.8
Not reported 4,052 9.3 2,401 11.3
Disability grade at end of treatment
Grade 0 18,486 42.2 9,112 42.9
Grade 1 3,728 8.5 2,253 10.6
Grade 2 1,240 2.8 784 3.7
Not reported 20,320 46.4 9,095 42.8
Reaction episodes
No reaction 14,116 32.2 14,097 66.4
Type 1 2,476 5.7 1,901 8.9
Type 2 751 1.7 485 2.3
Types 1 and 2 357 0.8 209 1.0
Not reported 26,074 59.6 4,552 21.4
Treatment outcome
Cure 38,209 87.3 17,223 81.1
Dropout 2,339 5.3 1,211 5.7
Transferred health unit 2,584 5.9 2,421 11.4
Death 642 1.5 389 1.8
Average number of recorded contacts 3.7 2.4 3.2 2.3
Average number of examined contacts 2.1 2.3 2.8 2.2
Our study provides evidence that leprosy remains endemic in Brazil as of 2017 (10.2/100,000), 
with strong heterogeneity and hyperendemic areas (> 20/100,000) in the North and Central West 
regions of the country. The Brazilian leprosy NCDR remains higher than across the World Health 
Organization (WHO) regions such as Americas (2.86/100,000) or in other endemic regions, such as 
Southeast Asia (7.72/100,000) 8,9,10.
These data also indicate that Brazil continues to have a very high incidence of infection among 
children under 15 years of age 11. This high burden in the pediatric population may reflect early infec-
tion of children and teenagers arising from sustained disease transmission associated with low detec-
tion rates and lack of timely treatment in adults with multibacillary leprosy 12,13. Studies carried out 
previously in Brazil, Saudi Arabia, Mexico, and South Korea provide evidence of a decreasing trend in 
the number of new leprosy cases among those under 15 years, which has been mainly attributed to the 
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Figure 2
Frequency of new case detections of leprosy by grade of physical disability at diagnosis for the overall population and for children under 15 years old in 
Brazil from 2006 to 2017.
provision of multidrug-therapy, contact surveillance and immunoprophylaxis 5,14,15. An evaluation of 
the Brazilian Unified National Health System (SUS) achievements in tackling communicable diseases 
demonstrated that, despite the efforts taken in the last 30 years to control leprosy, they have not been 
able to fully control the disease transmission, with leprosy NCDR in children as a salient indicator of 
persistent circulation of M. leprae 15,16.
The higher NCDR among men and the consistent male:female ratio across all years demonstrates 
an imbalance in leprosy distribution by sex in Brazil. Differences in morbidity between men and 
women can be determined by social factors related to lifestyle, habits, culture, and behavior 17,18. 
In general, men may be more vulnerable to illness and more severe forms, mainly due to their poor 
healthcare seeking behavior coupled with scarcity of specific services addressing their needs 17. 
Although NCDRs remain high among children, the increased leprosy trend observed among older 
adults 19,20 and the increasing number of multibacillary cases are also consistent with the patterns 
observed in high-income countries, where leprosy was eliminated in the past century 15,21,22,23. 
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Figure 3
Distribution of grades of physical disabilities at the diagnosis and in the end of treatment in Brazil in 2006 and in 2017.
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Table 5
The distributions of sociodemographic and clinical variables for individuals with grade 2 disabilities (G2D) at diagnosis in 
Brazil from 2006 to 2017.
Variables 2006 (n = 4,144) 2017 (n = 1,436)
n % n %
Sex
Female 718 29.7 437 30.4
Male 1,698 70.3 999 69.6
Age group (years)
< 15 63 2.6 39 2.7
15-59 1,571 65.0 821 57.2
60+ 782 32.4 576 40.1
Race/Ethnicity
White 867 35.9 387 26.9
Brown/Mixed race 1,063 44.0 795 55.4
Black 349 14.4 197 13.7
Asian 30 1.2 11 0.8
Indigenous 11 0.5 6 0.4
Not reported 96 4.0 40 2.8
Level of education
Primary education or lower 1,850 76.6 887 61.8
Secondary education or higher 290 12.0 301 21.0
Not reported 276 11.4 248 17.3
Region of residence
North 387 16.0 304 21.2
Northeast 842 34.9 552 38.4
Southeast 731 30.3 317 22.1
South 169 7.0 65 4.5
Central West 286 11.8 197 13.7
Not reported 1 0.0 1 0.1
Table 4
Summary table of disability grade at diagnosis versus end of treatment in Brazil from 2006 to 2017 (N = 396,989).
At diagnosis Total At end of treatment
G0D G1D G2D Grade not reported
n % n % n % n %
2006
G0D 29,811 15,037 50.4 1,282 4.3 235 0.8 13,257 44.5
G1D 7,495 2,087 27.8 1,929 25.7 283 3.8 3,196 42.6
G2D 2,416 387 16.0 282 11.7 637 26.4 1,110 45.9
Not reported 4052 975 24.1 235 5.8 85 2.1 2,757 68.0
2017
G0D 12,375 6,831 55.2 509 4.1 86 0.7 4,949 40.0
G1D 5,032 1,447 28.8 1,459 29.0 141 2.8 1,985 39.4
G2D 1,436 192 13.4 129 9.0 502 35.0 613 42.7
Not reported 2,401 642 26.7 156 6.5 55 2.3 1,548 64.5
Note: grade of physical disability (grade 0 – G0D, grade 1 – G1D, and grade 2 – G2D).
(continues)
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Table 5 (continued)
Variables 2006 (n = 4,144) 2017 (n = 1,436)
n % n %
Residential area
Urban 1,441 59.6 1,141 79.5
Rural 339 14.0 251 17.5
Not reported 636 26.3 44 3.1
Clinical form
Indeterminate 55 2.3 48 3.3
Tuberculoid 256 10.6 79 5.5
Borderline 1,066 44.1 783 54.5
Lepromatous 858 35.5 426 29.7
Not evaluated 181 7.5 100 7.0
Operational classification
Paucibacillary 293 12.1 78 5.4
Multibacillary 2,119 87.7 1,358 94.6
Not evaluated 4 0.2 0 0.0
Reaction
No reaction 780 32.3 809 56.3
Type 1 220 9.1 226 15.7
Type 2 100 4.1 66 4.6
Types 1 and 2 44 1.8 39 2.7
Not evaluated 1,272 52.6 296 20.6
Reported treatment outcome
Cure 1,992 82.5 1,072 74.7
Dropout 119 4.9 77 5.4
Transferred health unit 195 8.1 216 15.0
Death 110 4.6 71 4.9
However, the fact that the disease is more frequent among the individuals self-identified as Black 
and those with a lower level of education, which may be considered proxy variables for social and 
economic inequality, our results also reinforce the idea of there being social determinants of leprosy 
in Brazil and disparities in awareness of the disease and access to health services 24,25. In Brazil, 
individuals identifying as Black have historically experienced racial discrimination associated with 
reduced access to education, fewer work and income opportunities, and poorer household living 
conditions 25,26 – social factors that may increase susceptibility to infectious diseases.
While the increased proportion of multibacillary cases indicates a reduction of leprosy endemic-
ity, the increased proportion of G1D and G2D and still high NCDR among children indicates late 
diagnosis and inadequately detected and persistent transmission of M. leprae 13.
In 2017, 7.6% of the leprosy cases in Brazil were diagnosed with G2D at the time of detection, 
higher than the 5.8% observed around the world in 2017, and among other endemic countries like 
India (3.6%) and Indonesia (0.7%) 27. A recent population-based study evaluating low-income people 
in Brazil found a high incidence of leprosy among household contacts of patients with multibacillary 
leprosy (772.1/100,000 person-year) and with G2D (852.1/100,000 person-year) 28, suggesting that 
severe forms of leprosy may be associated with an increase of transmission. The increase in propor-
tions of physical disabilities observed over the years suggests that it is still necessary to strengthen 
contact tracing and active case finding in high-incidence areas to improve timely leprosy detection 
in the country 1.
Furthermore, the deficits in evaluation of the presence of leprosy-associated physical disabilities 
at the end of treatment suggests limitations in healthcare capacity and reinforce the need for reducing 
health disparities and increasing availability of health services 9. On the other hand, the large propor-
tion of cases transferred to other health units from 2006 to 2017 might suggest decentralization of 
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treatment, which started with the family health program implementation and that became a priority 
for leprosy after 2006. A previous study that took place in a cluster of leprosy in Brazil (2001-2009) 
observed that a high percentage of municipalities (93.6%) have reported detecting at least one leprosy 
case outside their municipality, sometimes derived from communities more than 1,000km away 29. 
These data suggest gaps in the capacity of the decentralized Brazilian health system to detect and 
provide comprehensive health care to individuals affected by leprosy 29.
The concentration of leprosy cases among individuals self-identified as Black, Brown, and Indig-
enous and living in the poorest regions of Brazil, along with the still high proportion of cases that are 
detected with disabilities and the high number of cases among children reinforces the fact that leprosy 
remains a public health problem and that early and universally accessible diagnosis still represents an 
important priority and challenge for leprosy control in the country. Therefore, achieving the control 
strategy goals requires universal health coverage, with a focus on children. In addition, the country 
needs an increase in social and financial support, strategies to fight stigma, and intersectoral activities 
to reduce social and health inequalities, especially racial disparities 9. Strategies such as conditional 
cash transfer programs – as Bolsa Família Program – have been associated with a reduction in leprosy 
detection rates in adults and children 24,30, and have recently been associated with higher leprosy 
treatment adherence and cure by acting on the social determinants of this and other poverty-related 
diseases 31. However, leprosy continues to disproportionately affect the more deprived regions and 
vulnerable populations in Brazil.
The Global Leprosy Strategy (2016-2020) was directed at “Acceleration towards a world without 
leprosy” and incorporated guidelines establishing three main objectives: (i) zero children diagnosed 
with leprosy with G2D; (ii) reduction to less than 1 case/million inhabitants of new cases of leprosy 
with G2D at diagnosis; (iii) and zero countries with legislation that allows for discrimination against 
leprosy 9. Therefore, our data suggest that Brazil has not yet met leprosy-related disability targets. 
However, these were broad objectives and difficult to achieve in a five-year plan. WHO has a new 
Global Leprosy Strategy (2021-2030) 32 – “Towards zero leprosy” –, which is focused on interrupting 
transmission, achieving zero autochthonous cases, and include a more specific care to persons suf-
fering from physical treatment, socioeconomic rehabilitation and mental health impact of leprosy. 
These bold targets will need even greater funding and political will to provide healthcare that can 
improve early detection and treatment across all endemic regions of Brazil and that will reach the 
most affected and vulnerable subgroups.
The interpretation of the results of this study should be done with caution due to the use of sec-
ondary data. These data are likely to still represent a underestimation of true incidence of leprosy in 
Brazil due to (i) poor data completion and possible inconsistencies in the quality of the information 
and (ii) under-reporting of cases that possibly occur among the poorest individuals and in poorest 
areas of Brazil 31. Additionally, trends have to be interpreted carefully as we did not perform a time 
series analysis.
Despite these limitations, the analysis and interpretation of these findings contribute to the devel-
opment and evaluation of leprosy surveillance activities in Brazil, suggesting the need to reinforce 
active case finding and continuous monitoring of leprosy patients after multidrug-therapy (MDT), 
especially after the increasing primary resistance to MDT in Brazil and elsewhere 33,34.
Our results demonstrate some weaknesses of health services in implementing leprosy control 
actions, especially those related to diagnosis and timely treatment. In addition, these findings rein-
force the need to discuss financing for the control of neglected diseases, such as leprosy, as well as 
the development of new technologies for their diagnosis and treatment. Finally, we highlight that less 
attention is given to strategies that aim to improve socioeconomic determinants of leprosy and to 
reduce inequalities in leprosy diagnosis. Leprosy should be included on the social protection agenda 
to ensure that affected people become priority beneficiaries in specific programs, such as Bolsa Família 
Program or as a priority group of social housing programs, such as Minha Casa Minha Vida [My House, 
My Life Program]. Social protection strategies focusing on leprosy control are especially important in 
the context of recent increase in leprosy cases in Brazil in the previous year (Brazilian Health Infor-
matics Department. http://tabnet.datasus.gov.br, accessed on 28/Nov/2019) and could be specifically 
targeted to improve contact tracing, reduce stigmatizing disabilities and prevent further transmission.
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Conclusions
This study indicates that there was a decreasing trend of leprosy detection rates in Brazil between 
2006 and 2017. However, leprosy remains hyperendemic in some regions, and continues to dis-
proportionately affect male, older and Black, Brown and Indigenous populations. Our results rein-
force the urgent need to define and strengthen public health interventions targeting people affected 
by severe forms of leprosy in order to reduce disabilities and stigma, and decrease transmission. 
Although advances have been observed in health service coverage and social protection programs 
in recent years, the results indicate the need for recognition, prevention and control actions in areas 
at highest risk of transmission. We suggest that prioritizing health education activities, active search 
and contact tracing, and timely treatment using multidrug-therapy are needed to prevent and treat 
leprosy-related disabilities.
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Resumo
O estudo teve com objetivos descrever as tendên-
cias na taxa de detecção de casos novos (TDCN) 
de hanseníase no Brasil em 2006-2017, global e 
por subgrupos, e analisar a evolução das caracte-
rísticas clínicas e terapêuticas dos pacientes, com 
ênfase nos casos diagnosticados com incapacidade 
física grau 2. Realizamos um estudo descritivo par 
analisar casos novos de hanseníase registrados no 
Sistema de Informação de Agravos de Notificação 
(SINAN), 2006-2017. Calculamos a TDCN de 
hanseníase por 100.000 habitantes (global e para 
indivíduos < 15 e ≥ 15 anos de idade) por sexo, 
idade, raça/etnicidade, área urbana/rural e ma-
crorregião do Brasil e estimamos as tendências 
com o teste não paramétrico de Mann-Kendall. 
Analisamos as distribuições de casos de acordo 
com características clínicas relevantes ao longo 
do tempo. No Brasil, houve uma queda marcante 
na TDCN global, de 23,4/100.000 em 2006 para 
10,3/100.000 em 2017; entre crianças < 15 anos, 
de 6,94 para 3,20/100.000. A queda foi consistente 
em todas a regiões brasileiras e em todas as catego-
rias de raça/etnicidade. Até 2017, 70,2% dos casos 
eram multibacilares, 30,5% apresentavam incapa-
cidades físicas grau 1 (G1D) ou grau 2 (G2D) ao 
diagnóstico e 42,8% não foram avaliados ao encer-
ramento do tratamento ou alta; os casos com G2D 
ao diagnóstico foram detectados majoritariamente 
nas áreas urbanas (80%), e 5% dos casos faleceram 
durante o tratamento (devido à hanseníase ou por 
outras causas). Embora a frequência da TDCN da 
hanseníase tenha diminuído no Brasil entre 2006 
e 2017 em todos os grupos avaliados, o número 
grande de casos com hanseníase multibacilar, in-
capacidades físicas ou sem avaliação adequada e 
entre crianças sugere a necessidade de reforçar o 
diagnóstico e tratamento oportunos para controlar 
a hanseníase no Brasil.
Hanseníase; Condições Sociais; Doenças 
Negligenciadas; Epidemiologia; Estudos  
de Séries Temporais
Resumen
Se realizó este trabajo con el fin de describir la 
tendencia general y en subgrupos de la tasa de de-
tección de nuevos casos de lepra (NCDR por sus 
siglas en inglés) en Brasil, entre 2006-2017, así 
como para analizar la evolución de las caracterís-
ticas clínicas y de tratamiento de los pacientes, con 
énfasis en los casos diagnosticados con un grado 
2 de discapacidad física. Realizamos un estudio 
descriptivo para analizar los nuevos casos de lepra 
registrados en el Sistema Brasileño de Información 
de Enfermedades de Notificación (SINAN), 2006-
2017. Calculamos la NCDR de lepra por cada 
100.000 habitantes (general e individuos con una 
edad < 15 y ≥ 15 años) por sexo, edad, raza/etni-
cidad, áreas urbanas/rurales y regiones brasileñas, 
y estimamos las tendencias usando el test no para-
métrico de Mann-Kendall. Analizamos las distri-
buciones de casos según las características clínicas 
relevantes a lo largo del tiempo. En Brasil, hubo 
una drástica disminución en general de NCDR de 
los 23,4/100.000 en 2006, a los 10,3/100.000 en 
2017; entre niños < 15 años, desde los 6,94 a los 
3,20/100.000. El decremento fue consistente en 
todas las regiones brasileñas y categorías de raza/
etnicidad. En 2017, un 70,2% de los casos fueron 
multibacilares, un 30,5% tenían grado 1 (G1D) 
o 2 (G2D) discapacidad física en el diagnóstico y 
un 42,8% no fueron evaluados al completar el tra-
tamiento/ser dados de alta; casos con G2D en el 
diagnóstico fueron en su mayoría detectados en 
áreas urbanas (80%) y un 5% de los casos murie-
ron durante el tratamiento (lepra u otras causas). 
A pesar de la frecuencia de lepra los NCDR de-
crecieron en Brasil de 2006 a 2017, a través de to-
dos los grupos de población evaluados, el elevado 
número de casos con lepra multibacilar, discapaci-
dad física o sin una adecuada evaluación, y entre 
niños sugiere la necesidad de reforzar a tiempo el 
diagnóstico y tratamiento para controlar la lepra 
en Brasil.
Lepra; Condiciones Sociales; Enfermedades 
Desatendidas; Epidemiología; Estudios  
de Series Temporales
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